THE CHEMOURS COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26 USD | -2.80% |
|
-3.99% | -17.56% |
| May. 01 | Trans Mountain Pipeline's C$34-Billion Expansion Project Enters Commercial Service | MT |
| May. 01 | Transcript : The Chemours Company, Q1 2024 Earnings Call, May 01, 2024 |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -17.56% | 3.98B | C+ | ||
| +1.83% | 78.54B | B | ||
| +1.79% | 30.31B | C | ||
| +12.30% | 18.58B | B | ||
| -10.05% | 11.56B | B | ||
| +5.50% | 11.11B | A- | ||
| -7.50% | 9.81B | - | ||
| +6.21% | 9.69B | A- | ||
| +5.61% | 9.3B | C- | ||
| +4.66% | 8.33B | B |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CC Stock
- Ratings The Chemours Company
